Replication Study: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44

• DOI: 10.7554/elife.43511
• Publication Date: 2019-03-12T00:00:16Z
• Authors: Xuefei Yan; Beibei Tang; Biao Chen; Yongli Shan; Huajun Yang; ; Elizabeth Iorns; Rachel Tsui; Alexandria Denis; Nicole Perfito; Timothy M Errington
• Keywords: Male; 0301 basic medicine; replication; QH301-705.5; Science; Cell Separation; Mice, SCID; Cell Line; Mice; 03 medical and health sciences; Mice, Inbred NOD; Cell Line, Tumor; metastasis; LAPC4; Animals; Humans; Biology (General); Neoplasm Metastasis; 3' Untranslated Regions; Alleles; Cancer Biology; 2. Zero hunger; metascience; 0303 health sciences; Binding Sites; Q; R; Flow Cytometry; 3. Good health; Gene Expression Regulation, Neoplastic; MicroRNAs; HEK293 Cells; Hyaluronan Receptors; Reproducibility Project: Cancer Biology; Neoplastic Stem Cells; Medicine; miR-34a; Neoplasm Transplantation

As part of the Reproducibility Project: Cancer Biology, we published a Registered Report (Li et al., 2015), that described how intended to replicate selected experiments from paper ‘The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44’ (Liu 2011). Here report results. We found microRNA, miR-34a, was expressed at twice level in CD44+ purified xenograft tumors (LAPC4 cells) compared CD44- LAPC4 cells, whereas original study reported underexpressed (Figure 1B; Liu When engineered express were injected into mice, did not observe changes tumor growth or CD44 expression; however, unexpectedly expression lost vivo. In study, expressing had statistically significant reduction regeneration reduced control 4A Supplemental Figures 4A,B 5C; Furthermore, when tested if regulated through binding sites 3’UTR find difference, decreased partially abrogated mutation 4D; Finally, where possible, meta-analyses for each result.